Cerluten
Research OnlyA cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Brain cytamin · Cerebral peptides · A-5 brain peptides
Mostly preclinical · 1 human study
- Preclinical
- 75%
- Clinical
- 13%
Based on 8 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research depth low: cytamin-class brain complex with only uncontrolled Russian observational human data and a small preclinical base, no RCTs. Mechanism partial: Khavinson short-peptide gene-regulation framework is characterized for defined peptides but Cerluten is an undefined tissue mixture, weakening target attribution. Plausibility moderate: neuroprotective claims cohere with peptide-bioregulator biology yet rest on unproven oral bioavailability and surrogate links. Global coverage limited: research concentrated in one Russian group with little independent replication. Community experience minimal: negligible documented real-world use. Effectiveness not established: no quantified human efficacy estimate and no meaningful community effect signal.
Mechanism of Action
Cerluten is a cytamin-class supplement containing peptide complexes derived from brain tissue.
Cytamin Classification
Cytamins are oral supplements in the Russian bioregulator framework:
- Tissue-derived peptide mixtures
- Multiple peptide fractions
- Marketed as dietary supplements
- Not defined single compounds
Proposed Mechanisms
- Neuroprotection - Claimed to support neuronal cell function
- Cognitive Support - Proposed effects on memory and cognition
- Age-Related Decline - Marketed to address cognitive aging
Important Limitations
- NOT a defined peptide - contains complex mixture
- Oral peptide bioavailability is generally very low
- No Western clinical validation
- No randomized controlled trials for cognitive outcomes
- Not approved by any Western regulatory agency
- NOT a treatment for dementia or cognitive disorders
Cortexin
CompatibleBoth target brain function - Cortexin is injectable brain extract with more clinical data, Cerluten is oral cytamin supplement.
Pinealon
CompatibleBoth target brain/cognitive function - Pinealon is synthetic tripeptide, Cerluten is tissue-derived complex.
Semax
CompatibleBoth Russian nootropic peptides - Semax is defined heptapeptide with more research, Cerluten is cytamin supplement.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Cerluten
Related Peptides
Alixorexton
ALKS 2680 · ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070 · N-PEP-12 · Renacenz
Cerebrolysin is a porcine brain-derived peptide mixture approved in 50+ countries for stroke, dementia, and traumatic brain injury. It is NOT FDA-approved in the United States despite decades of international clinical use. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. Mixed Phase 3 results but positive meta-analyses and widespread adoption in Europe, Asia, and Latin America.
Dihexa
PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide · Delta Sleep-Inducing Peptide · WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.
N-Acetyl Selank Amidate
NA-Selank · N-Acetyl Selank · Acetyl-Selank-Amidate +1
A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.
N-Acetyl Semax Amidate
NA-Semax · N-Acetyl Semax · Acetyl-Semax-Amidate +1
A chemically modified version of Semax with N-terminal acetylation and C-terminal amidation designed to enhance peptide stability. While parent Semax is approved in Russia for nootropic and neuroprotective applications, this specific modification has no independent clinical research.